GENNIEFY
Market News
Latest financial news and analysis from global markets
MSFT
Gary Black Says Tesla's 8-Week Slide Driven By 'Disappointing' Deliveries, Robotaxi Doubts: 'EVs Still Comprise 70%...'
Investor Gary Black, who is a managing partner at The Future Fund LLC, has outlined his take on why Tesla, Inc. has been declining for the past eight weeks. Disappointing Deliveries On Thursday, the investor shared why he thought TSLA stock was on the decline in a post on the social media platform X. He said the stock was declining after analysts cut earnings estimates following the automaker’s “disappointing” first-quarter 2026 delivery figures. “TSLA P/E being re-rated down as investors questi
AMZN
Gary Black Says Tesla's 8-Week Slide Driven By 'Disappointing' Deliveries, Robotaxi Doubts: 'EVs Still Comprise 70%...'
Investor Gary Black, who is a managing partner at The Future Fund LLC, has outlined his take on why Tesla, Inc. has been declining for the past eight weeks. Disappointing Deliveries On Thursday, the investor shared why he thought TSLA stock was on the decline in a post on the social media platform X. He said the stock was declining after analysts cut earnings estimates following the automaker’s “disappointing” first-quarter 2026 delivery figures. “TSLA P/E being re-rated down as investors questi
TSLA
Prediction: A Cheaper EV Could Be a Game Changer for Tesla's Business
The company hasn't said its last word.
INTC
Prediction: A Cheaper EV Could Be a Game Changer for Tesla's Business
The company hasn't said its last word.
NVDA
Prediction: A Cheaper EV Could Be a Game Changer for Tesla's Business
The company hasn't said its last word.
GS
How The Colgate Palmolive (CL) Investment Story Is Shifting With New Targets And 2030 Plan
Colgate-Palmolive’s modeled fair value has been trimmed slightly from US$97.26 to US$96.68 per share, a change of about US$0.58 that keeps the overall valuation view broadly intact while acknowledging updated inputs. That small adjustment sits against mixed Street commentary, where some analysts highlight the long term 2030 plan and others flag cost and valuation risks that have led to price targets moving both higher and lower. Read on to see how these shifting targets, recent news, and new...
BAC
How The Colgate Palmolive (CL) Investment Story Is Shifting With New Targets And 2030 Plan
Colgate-Palmolive’s modeled fair value has been trimmed slightly from US$97.26 to US$96.68 per share, a change of about US$0.58 that keeps the overall valuation view broadly intact while acknowledging updated inputs. That small adjustment sits against mixed Street commentary, where some analysts highlight the long term 2030 plan and others flag cost and valuation risks that have led to price targets moving both higher and lower. Read on to see how these shifting targets, recent news, and new...
CL
How The Colgate Palmolive (CL) Investment Story Is Shifting With New Targets And 2030 Plan
Colgate-Palmolive’s modeled fair value has been trimmed slightly from US$97.26 to US$96.68 per share, a change of about US$0.58 that keeps the overall valuation view broadly intact while acknowledging updated inputs. That small adjustment sits against mixed Street commentary, where some analysts highlight the long term 2030 plan and others flag cost and valuation risks that have led to price targets moving both higher and lower. Read on to see how these shifting targets, recent news, and new...
JNJ
Johnson & Johnson (JNJ) Valuation Check As TECNIS PureSee IOL Data Take Center Stage
Johnson & Johnson (JNJ) is back in the spotlight after presenting extensive clinical and real world data for its recently FDA approved TECNIS PureSee intraocular lens at the ASCRS 2026 meeting in Washington, DC. See our latest analysis for Johnson & Johnson. Those TECNIS PureSee data arrive at a time when Johnson & Johnson’s share price has shown strong momentum over the past quarter, with a 90 day share price return of 16.67% and a 1 year total shareholder return of 61.54%, even though...
NKE
Nike’s UEFA Ball Deal Puts Brand Exposure And Valuation In Focus
Nike is reportedly close to becoming the official match ball provider for the UEFA Champions League. The deal would end Adidas's 25 year run as ball supplier for Europe's top club competition. The reported agreement is also expected to cover the Europa League and Conference League. Nike, traded as NYSE:NKE, is seeing this branding news arrive after a weak share price patch, with the stock at $42.62. The share price shows declines of 3.6% over the past week, 23.5% over 30 days, and 32.6%...
ETHUSDT
$1.5 Billion Ethereum Treasury Ether Machine Deal Collapses
The Ether Machine terminates its SPAC merger with Dynamix, citing unfavorable market conditions amid ETH's sharp decline from its 2025 highs.
INTC
3 Dividend Stocks That Are Obvious Buys in Today's Uncertain Market
When markets get shaky, the stocks you trust most tend to be the ones built to last. Here are three strong dividend buys as money gets tight.